NANOTEC and GPO to upgrade drug innovation in Thailand
To support projected growth of pharma market in the region
The partnership will help upgrade the research capabilities of the two Thai agencies and promote national competitiveness, said Soontorn Vorakul, acting managing director for the GPO.
‘The focus of the research collaboration will be in the area of cosmeceutical and drug delivery using nanotechnology,’ he said.
Professor Sirirurg Songsivilai, executive director of NANOTEC, added that the opportunities for nanotechnology in pharmaceutical manufacturing and development are enormous.
‘It is clear that the international pharmaceutical industry has embraced nanotechnology research in their manufacturing. It is essential for the GPO and NANOTEC to join forces and share expertise if we are to keep pace with drug discovery,’ he said.
Thailand will be the eighth largest economy in the Asia Pacific region by 2016, according to the Economist Intelligence Unit (EIU). GDP growth is projected to increase to 7.1% in the same period.
The EIU also projects an annual growth rate of around 0.7% and the population to be the ninth largest in the Asia Pacific region in five years’ time. The elderly population is also rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region by 2016.
By 2016 it is estimated that Thailand will have the seventh largest pharmaceutical market in the Asia Pacific region.
You may also like
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Read morePoolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Trending Articles
You may also like
Research & Development
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development
Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend
Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Research & Development
Global myalgic encephalomyelitis study identifies 250+ core genes and shared biology with long COVID
PrecisionLife’s large-scale genomic analysis reveals major biological drivers of ME and its overlap with long COVID, identifying dozens of drug repurposing opportunities and paving the way for more targeted clinical trials
Research & Development
Servier and University College London partner to advance research in rare genetic epileptic disorders
Servier will collaborate with UCL to evaluate antisense oligonucleotide candidates in cutting-edge brain assembloid models, aiming to accelerate therapeutic advances for patients with developmental and epileptic encephalopathy (DEE)
Research & Development
EU chemicals reforms rarely reflected in pharmaceutical policy, new study finds
A new analysis shows major EU Green Deal-driven chemicals legislation changes are seldom integrated into pharmaceutical policy, highlighting the need for closer alignment between health and environmental regulation